The Virtual Press Room is a courtesy for corporate and institutional public relations professionals. Publication of material on this page does not constitute an endorsement by ASCO of any product or claim. For information about how to submit a press release to the Virtual Press Room, visit the For PR Professionals page.

2019 ASCO Annual Meeting

Ambry Genetics
Research from Ambry Genetics & Mayo Clinic Reveals Differences in the Prevalence of Breast Cancer Genes among Racial and Ethnic Populations

Cancer Research UK
LESS CHEMOTHERAPY BETTER FOR OLDER OR FRAIL PATIENTS WITH ADVANCED STOMACH AND OESOPHAGEAL CANCERS

Dana-Farber Cancer Institute
Dana-Farber researchers present findings in more than 70 research studies at ASCO annual meeting 2019

Epizyme
Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting

Fox Chase Cancer Center
Combination of Axitinib and Nivolumab Safe for Patients with Metastatic Renal Cell Carcinoma, Efficacy Testing Ongoing

Georgetown/Lombardi Comprehensive Cancer Center
Patient Groups Untested in Cancer Immunotherapy Trials Found to Also Benefit

Janssen
ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC

Phase 3 COLUMBIA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma

DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant

IMBRUVICA® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)

Levine Cancer Institute
Levine Cancer Institute to present first-of-its-kind and practice-changing research at the 2019 ASCO Annual Meeting

Mylan and Biocon
Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting

Northwestern Medicine
Northwestern Medicine oncologists and researchers present findings at 2019 ASCO Annual Meeting

Novotech
Novotech Awarded Asia-Pacific Biotech CRO of the Year - Announced at ASCO

Sarah Cannon
Sarah Cannon to Present Latest Cancer Research Insights at 2019 American Society of Clinical Oncology's Annual Meeting

University of Colorado Cancer Center
Cancer care providers see benefit of medical marijuana, but not comfortable prescribing